Loading clinical trials...

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers | Clinical Trials | Clareo Health

UNKNOWNPHASE2

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study

NCT04211168•Peking Union Medical College Hospital

View on ClinicalTrials.gov

Summary

The investigators design a phase II clinical study to explore the efficacy and safety of toripalimab plus lenvatinib as a second-line treatment in patients with advanced biliary tract cancers and to analyze potential biomarkers of therapeutic response.

Detailed Description

This phase II trial is a single-arm, non-randomized and single-center clinical study. It is estimated that 44 patients who met the study criteria will be enrolled in 2 years and treated with toripalimab plus lenvatinib in PUMCH. The investigators will follow up and collect subjects' data each month to evaluate the efficacy and safety of treatment, including overall survival and time to progression, until disease progression or death. Interim analysis and final analysis will be conducted when collecting data from 20 and 44 subjects, respectively in this trial. Histopathology and multi-omics data analysis will be used to explore potential biomarkers of treatment response. Study Type: Interventional. Masking: Open Label.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects volunteer to participate in the study and agree to sign the informed consent with good compliance and follow-up.
•Subjects are 18 years old or older when signing the informed consent and gender is not limited.
•Subjects were diagnosed with advanced biliary tract cancers by imaging and histological examination, including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, common bile duct cancer and gallbladder cancer. Advanced biliary tract cancers refer to unresectable, recurrent, locally advanced and metastatic lesions which are defined as stage IIIA or above according to the 8th AJCC stage system.
•The disease is not suitable for radical surgery and/or topical treatment, or disease progression occurs after surgery and/or local treatment, including lesion resection, ablation, transcatheter arterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), radiotherapy at least 4 weeks before the baseline assessment. All acute toxic effects of local treatment must be ≤ CTCAE 5.0 Level 1.
•Patients are intolerant or fail after first-line systemic treatment (gemcitabine or platinum based regimen) and require palliative treatment. The first-line system treatment failure was ≥ 1 month before enrollment in this study (signing informed consent) and adverse events are controlled (NCI-CTCAE ≤ Grade Ⅰ). i) Definition of systemic treatment: Gemcitabine or platinum based regimen for more than 1 cycle. Adjuvant chemotherapy based on gemcitabine or platinum is considered as first-line treatment if recurrence occur during or after 6 months adjuvant chemotherapy sequential to tumor resection. ii) Definition of treatment failure: Disease progression occur during treatment or in 6 months after the last cycle. iii) Definition of intolerance: Grade ≥IV hematologic toxicity; grade ≥III toxicity of liver, kidney and skin; grade ≥ II toxicity of heart, lung and brain.
•Prior treatment must not include lenvatinib, PD-1 / PD-L1 antibodies or molecular targeted therapy for ≥ 14 days.
•At least one measurable lesion (according to RECIST version 1.1): the measurable lesion has a long diameter ≥ 10 mm or lymphadenopathy has a short diameter ≥ 15 mm in spiral CT scan.
•Blood pressure is controlled \<= 150/90 mmHg with no more than 3 antihypertensive drugs.
•The ECOG score is 0-1 within 1 week before enrollment.
•Estimated survival time ≥ 12 weeks.
+8 more criteria

Exclusion Criteria

•Patients meet with any of the following condition: Suitable for radical surgery; Or, without an assessment lesion after radical surgery; Or, never receive any first line treatment.
•Patients who received first-line chemotherapy within 1 month when participating in the study.
•Already known to be allergic or intolerant to recombinant humanized PD-1 monoclonal antibody drugs (or components) or lenvatinib.
•Previously received with lenvatinib, or any anti-vascular endothelial growth factor (VEGF) or VEGF receptor targeted drug, or any anti-PD-1, anti-PD-L1 or anti-PD-L2 or CTLA-4 drug, including antibodies involved in JS001 clinical studies.
•ECOG score ≥ 2 points.
•Hepatic encephalopathy.
•Histopathological result show mixed liver cancer, squamous cell carcinoma or sarcoma cell component.
•More than 2 organs metastasis, including liver, lung, bone and brain.
•pregnant women (positive pregnancy test before taking the drug) or lactating women.
•Patients with bone metastases who had received palliative radiotherapy within 4 weeks before participating in the study (radiotherapy area\>5% bone marrow area).
+36 more criteria

Locations (1)

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

August 11, 2020

Primary Completion Date

July 1, 2024

Completion Date

December 1, 2024

Last Updated

March 29, 2023

Enrollment

ESTIMATED participants

Conditions

Advanced Biliary Tract Cancer

Interventions

Toripalimab plus Lenvatinib

DRUG

Contacts

Xiaobo Yang, MD

CONTACT

010-69156043 yangxulcyx@163.com

Haitao Zhao, MD

CONTACT

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

NCT04172402

Advanced Biliary Tract Cancer

View study

COMPLETEDPHASE2

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

NCT04217954

Advanced Biliary Tract Cancer

View study

TERMINATEDPHASE2

Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer

NCT01096745

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 29, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions